Authors
Latest:
A New Phase in MedicineHow the merging of medical faculty and academic hospitals in The Netherlands is improving the country's research infrastructure.
Latest:
Business and People Update February 2010Industry news focusing on the people and organizations who work in the clinical trials profession.
Latest:
Pediatric Research in GermanySurveys among pharma, clinics, and investigators shed light on trials in children.
Latest:
Steps to Functional Service Provider SuccessOutsourcing fundamentals for this pick-and-choose model so that both sponsors and service providers win.
Latest:
Making Medical Writing a PriorityFinding a strategic approach to writing clinical study reports.
Latest:
Q&A: Assessing the Strides Made So Far in AI’s Clinical Trial AscentMick Ryan, vice president of IT at ICON plc, discusses the growing use of artificial intelligence in clinical research—from technology and data analysis to patient privacy and ethics.
Latest:
ICH E6(R3) Ushers in the Risk Based Quality Management Era – But Are We Ready?Collaboration and regulation were the watchwords at DIA Global this year, where the ICH E6(R3) guideline, published in final draft form in May, was the talk of the congress.
Latest:
Predicting the Probability of Success in Clinical Drug DevelopmentUndertaking an assessment of the POS can be coupled with the product profile and safety assessments of compounds prior to launching a clinical trial.
Latest:
Strategic Comparator SourcingEffective ways for sponsors to reduce risk when embarking on comparative clinical trials.
Latest:
Letting Investigators LeadPerspectives on adoption of technology at U.S. Academic Medical Centers and how sponsors will be impacted.
Latest:
Preapproval OpportunitiesIntegrating clinical trials and named patient programs to provide global access to drugs before approval.
Latest:
Can We Predict Drug Efficacy with Artificial Intelligence?Approaches such as machine learning, AI and neural networks are still in their infancy, but with AI companies rewriting the code for drug discovery, the implications in pharma are likely to be far ranging in the coming years.
Latest:
Forecast Enrollment Rate in Clinical TrialsInstinctively, when there are more investigators/sites being deployed for a trial with a defined number of patients needed, we should expect shortened enrollment cycle time. This sounds right, but is it really?
Latest:
Strategy FirstAn integrated product development plan designed early increases the odds of on time success.
Latest:
Promoting Clinical Trials in JapanLaunched in 2003, the LCN Project calls for more studies and an improved trial infrastructure.
Latest:
Objective Internal MonitoringSponsors are responsible for monitoring studies, patient safety, and data integrity.
Latest:
Promoting Clinical Trials in JapanLaunched in 2003, the LCN Project calls for more studies and an improved trial infrastructure.
Latest:
From Cradle to GraveTracking the life cycle of a drug is a complex process that early planning and IVR technology can help ease.
Latest:
Evaluating the Effects of Therapy MaskingUsing a specific trial, the importance of assessing the success of therapy masking is examined.
Latest:
Cost and Quality Implications of RBMThis is the third post in a three-part series on quality implications of RBM.
Latest:
Small Biopharm Firms Struggle to Meet Development ChallengesThe temptation to use uncontrolled, early, small studies to support further development of products may prove problematic for emerging biopharma companies.
Latest:
Promoting Clinical Trials in JapanLaunched in 2003, the LCN Project calls for more studies and an improved trial infrastructure.
Latest:
Reverse Auctions: Crusade or Curse?In this Web-based strategy, suppliers bid "down" prices for the privilege to sell their products and services. Is big pharma sold?
Latest:
Reverse Auctions: Crusade or Curse?In this Web-based strategy, suppliers bid "down" prices for the privilege to sell their products and services. Is big pharma sold?
Latest:
Promoting Clinical Trials in JapanLaunched in 2003, the LCN Project calls for more studies and an improved trial infrastructure.
